Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (501-510 of 643) with videos related to

Pageof 65
Sort By:
Cancer|October 18, 2021
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specifiedLuana G Sousa, Kaiwen Wang, Danice Torman, et al.
Oncotarget|September 10, 2019
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
Journal of Immunotherapy and Precision Oncology|November 11, 2024
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic MelanomaMohamed A Gouda, Bettzy Stephen, Yanyan Tian, et al.
Gynecologic Oncology|November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancerShannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular SubtypesJonathan M Loree, Allan A L Pereira, Michael Lam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerAna M Gonzalez-Angulo, Jennifer K Litton, Kristine R Broglio, et al.
Cancer|January 11, 2005
Breast conservation after neoadjuvant chemotherapyAllen M Chen, Funda Meric-Bernstam, Kelly K Hunt, et al.
Oncotarget|April 19, 2017
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
JCO Precision Oncology|July 24, 2018
Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast CancerFunda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, et al.
Gynecologic Oncology Reports|April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinomaElizabeth H Stover, Niya Xiong, Andrea P Myers, et al.
Pageof 65

Showing results (501-510 of 643) with videos related to

Sort By:
Pageof 65
Cancer|October 18, 2021
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specifiedLuana G Sousa, Kaiwen Wang, Danice Torman, et al.
Oncotarget|September 10, 2019
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
Journal of Immunotherapy and Precision Oncology|November 11, 2024
A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic MelanomaMohamed A Gouda, Bettzy Stephen, Yanyan Tian, et al.
Gynecologic Oncology|November 24, 2022
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancerShannon N Westin, Siqing Fu, Apostolia Tsimberidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular SubtypesJonathan M Loree, Allan A L Pereira, Michael Lam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerAna M Gonzalez-Angulo, Jennifer K Litton, Kristine R Broglio, et al.
Cancer|January 11, 2005
Breast conservation after neoadjuvant chemotherapyAllen M Chen, Funda Meric-Bernstam, Kelly K Hunt, et al.
Oncotarget|April 19, 2017
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
JCO Precision Oncology|July 24, 2018
Survival Outcomes by <i>TP53</i> Mutation Status in Metastatic Breast CancerFunda Meric-Bernstam, Xiaofeng Zheng, Maryam Shariati, et al.
Gynecologic Oncology Reports|April 18, 2022
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinomaElizabeth H Stover, Niya Xiong, Andrea P Myers, et al.
Pageof 65